- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Not listed
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- ALN-4324, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
- Interventions
- R-5280, Placebo
- Drug · Other
- Lead sponsor
- Rise Therapeutics LLC
- Industry
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Plantation, Florida • Rochester, Minnesota • Dallas, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- XW014, Placebo
- Drug
- Lead sponsor
- Sciwind Biosciences USA Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- Interventions
- pioglitazone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Interventions
- GSK189075
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islets of Langerhans transplantation
- Biological
- Lead sponsor
- CellTrans Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Diseases
- Interventions
- CLBS201
- Drug
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
- Interventions
- GSK189075 oral tablets, GW869682 oral tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Chronic Kidney Disease
- Interventions
- Neo-kidney augment
- Biological
- Lead sponsor
- Tengion
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Escondido, California • La Jolla, California • San Mateo, California + 16 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 35
- States / cities
- Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more
- Conditions
- Type 1 Diabetes
- Interventions
- High Dose SAB-142, Low Dose SAB-142, Placebo
- Drug · Other
- Lead sponsor
- SAb Biotherapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Interventions
- LY2382770, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- chromium niacinate, placebo
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Type 1 Diabetes, Celiac Disease
- Interventions
- Gluten Challenge, Sham Challenge
- Dietary Supplement
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Rimonabant (SR141716), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus, Type I
- Interventions
- islets
- Drug
- Lead sponsor
- Rodolfo Alejandro
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Patients
- Interventions
- Empagliflozin, Dorzagliatin
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Encino, California • Fresno, California • Oakland, California + 25 more
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
- Interventions
- Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania